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Abstract 
The impact of maintenance therapy on progression‑free survival and overall survival as well as quality of life of Chi‑
nese patients with metastatic colorectal cancer has long been under discussion. Recently, some phase III clinical trials 
have revealed that maintenance therapy can significantly prolong the progression‑free survival while maintain an 
acceptable safety profile. Based on this evidence and common treatment practice in China, we now generated one 
Expert Consensus on Maintenance Treatment for Metastatic Colorectal Cancer in China to further specify the neces‑
sity of maintenance therapy, suitable candidates for such treatment, and appropriate regimens.
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Consensus
The incidence of colorectal cancer (CRC) has increased 
annually. CRC is one of the five most common cancers 
in Chinese males and females [1]. In recent years, the 
outcome of metastatic colorectal cancer (mCRC) has 
been significantly improved due to the introduction of 
novel drugs and biological agents. Patients are achieving 
improved parameters such as increased response rate, 
prolonged progression-free survival (PFS), and prolonged 
overall survival (OS). Several clinical trials demonstrated 
that patients who benefited from initial chemotherapy 
alone or in combination with targeted agents can also 
benefit from maintenance therapy by having prolonged 
time to disease recurrence or deterioration, prolonged 
PFS, delayed disease progression, and improved quality 
of life (QoL) [2–5]. Although there are several clinical tri-
als on maintenance therapy, none of them has provided 
guidance on the selection of candidates, regimens, and 
timing. Therefore, the present paper summarizes the evi-
dence and expert consensus from relevant clinical trials.
Necessity for and candidates of maintenance 
therapy
Definition of maintenance therapy and its necessity
Maintenance therapy is the continued use of less potent 
and toxic drugs when the maximum response stabilizes 
after a defined period of first-line treatment, such that 
the patient would have a prolonged PFS, few adverse 
effects (AEs), delayed recurrence of tumor-associated 
symptoms, and, consequently, an improved QoL.
Patients who have benefited from first-line standard 
chemotherapy alone or in combination with targeted 
treatment could have three options (Fig. 1; Table 1):
(1)   Continuous treatment: continued use of standard 
chemotherapy alone or in combination with tar-
geted agents until disease progression or intolerable 
toxicity occurs.
(2)   Maintenance treatment: a standard and potent regi-
men with highly toxic drugs is discontinued and 
replaced by a less potent maintenance regimen with 
less toxic drugs, which usually comprises a first-
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line drug and another drug or targeted agent with 
no cross-resistance to first-line treatment. Mainte-
nance treatment is usually used at a lower dose.
(3)   Intermittent treatment: complete discontinuation 
of chemotherapy and targeted drugs.
The prolonged use of standard chemotherapy alone or 
in combination with targeted agents will escalate drug 
toxicity. The accumulated neurotoxicity of the oxali-
platin-based protocol has contributed to the discon-
tinuation of chemotherapy in patients who consistently 
responded to chemotherapy. However, these patients 
would have an improved outcome if they switched to 
maintenance treatment with less potent and toxic drugs 
[2]. The OPTIMOX1 study revealed that maintenance 
treatment was comparable to continuous treatment with 
regard to its efficacy, but it significantly reduced AEs and 
improved the patients’ QoL [6].
The results from the OPTIMOX2 study confirmed 
that maintenance treatment is superior to intermittent 
treatment in terms of clinical efficacy [7]. In the OPTI-
MOX2 study, patients with mCRC discontinued chemo-
therapy (chemotherapy-free interval group), or they were 
switched to a simplified maintenance treatment with 
5-fluorouracil (5-FU) or leucovorin (LV) (maintenance 
group) following 6 cycles of modified FOLFOX7 until 
disease progression. The results showed that the main-



















Fig. 1 Schematic diagram of continuous, maintenance, and intermittent treatment patterns. FOLFOX [oxaliplatin, 5‑fluorouracil (5‑FU) plus folinic 
acid], FOLFIRI (irinotecan, 5‑FU plus folinic acid), CapeOx (capecitabine plus oxaliplatin), and FOLFOXIRI (oxaliplatin, irinotecan, 5‑FU plus folinic acid) 
regimens were used for combination chemotherapy. Bevacizumab or cetuximab was used as targeted agents. CR complete remission, PR partial 
remission, SD stable disease
Table 1 First-line treatment protocols for  patients with  metastatic colorectal cancer (mCRC) who are able to  tolerate 
highly intensified treatment
a The regimen can be used alone or in combination with bevacizumab (5 mg/kg in 2-week protocol or 7.5 mg/kg in 3-week protocol, IV on Day 1 of each cycle)
b The regimen can be used alone or in combination with panitumumab (6 mg/kg, IV > 60 min, repeated every 2 weeks) or cetuximab (only for patients with wild-type 
KRAS/NRAS; initial dose 400 mg/m2, IV > 2 h, and then 250 mg/m2, IV > 60 min once a week or 500 mg/m2 every 2 weeks)
Chemotherapy protocol Route and cycles of administration
FOLFOX (mFOLFOX6)a,b Oxaliplatin 85 mg/m2, intravenous infusion (IV) for 2 h on Day 1;
leucovorin (LV) 400 mg/m2, IV for 2 h on Day 1;
5‑fluorouracil (5‑FU) 400 mg/m2, IV on Day 1, and then 1200 mg/m2 continuous IV for 2 days (total dose 2400 mg/m2 for 
46–48 h)
Protocol repeated every 2 weeks
CapeOxa Oxaliplatin 130 mg/m2, IV for >2 h on Day 1;
capecitabine 850–1000 mg/m2, oral administration twice daily on Days 1–14, and then discontinued for 7 days
Protocol repeated every 3 weeks
FOLFIRIa,b Irinotecan 180 mg/m2, IV > 30–90 min on Day 1;
LV 400 mg/m2, IV for 2 h with irinotecan on Day 1;
5‑FU 400 mg/m2, IV on Day 1 and then 1200 mg/m2/d continuous IV for 2 days (total dose 2400 mg/m2 for 46–48 h)
Protocol repeated every 2 weeks
FOLFOXIRIa Irinotecan 165 mg/m2, oxaliplatin 85 mg/m2 plus LV 400 mg/m2, IV on Day 1;
5‑FU 1600 mg/m2 per day, continuous IV for 2 days (total dose 3200 mg/m2 for 48 h)
Protocol repeated every 2 weeks
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group in OS (23.8 vs. 19.5 months, P =  0.042) and PFS 
(8.6 vs. 6.6 months, P = 0.0017) [7].
Therefore, compared with the other two patterns, 
maintenance treatment after first-line treatment is essen-
tial for patients with mCRC, and it is an appropriate ther-
apeutic strategy for most patients.
Candidates for maintenance treatment
The benefit is maximized after 3–6  months of first-line 
treatment. Patients can present complete response (CR), 
partial response (PR), or stable disease (SD). However, 
those with mCRC who cannot tolerate the toxicity of 
continuous combination therapy alone or in combina-
tion with targeted drugs are candidates for maintenance 
treatment.
The results from the OPTIMOX2 study indicated 
that maintenance therapy can be suitable for high-risk 
patients with poor prognosis, whereas intermittent ther-
apy can be applied to low-risk patients with fair progno-
sis [7]. However, selecting indicators for candidates with 
improved outcomes at baseline levels are poorly defined; 
therefore, they deserve further study.
Protocols and duration of first-line treatment
Protocols of first‑line treatment
For patients with mCRC who can tolerate highly intensi-
fied treatment, first-line recommendations include FOL-
FOX [oxaliplatin, 5-fluorouracil (5-FU) plus folinic acid], 
FOLFIRI (irinotecan, 5-FU plus folinic acid), CapeOx 
(capecitabine plus oxaliplatin), and FOLFOXIRI (oxalipl-
atin, irinotecan, 5-FU plus folinic acid) regimens (Fig. 1) 
[8], all of which can be used in combination with bevaci-
zumab [8–12]. FOLFOX and FOLFIRI regimens can be 
combined with panitumumab or cetuximab (for patients 
with wild-type KRAS/NRAS only) [13].
Duration of first‑line treatment
Most patients will obtain maximum response after 
2–3  months of chemotherapy, and they are required to 
stop standard chemotherapy due to neurotoxicity and 
bone marrow suppression after 4–6  months. Clinicians 
must decide the duration of first-line treatment on the 
basis of balancing efficacy and safety.
The 2014 European society for medical oncology 
(ESMO) Clinical Practice Guidelines for diagnosis, treat-
ment, and follow-up of mCRC recommends a first-line 
treatment duration of 3–6 months [14]. Several phase III 
clinical trials suggested that if the patient obtains a maxi-
mum response after 3–6  months of first-line treatment, 
he/she can switch to maintenance therapy [5, 6, 15].
The National Comprehensive Cancer Network 
(NCCN) guidelines strongly recommend discontinu-
ation of oxaliplatin after 3  months of FOLFOX or 
CapeOx chemotherapy and even earlier if intolerable 
neurotoxicity occurs. The reminder drugs in the main-
tenance therapy are retained until 6 months or disease 
progression. Patients presenting signs of neurotoxicity 




Currently, targeted agents are not affordable to many Chi-
nese patients as a first-line treatment. For them, chemo-
therapy alone can be used as maintenance treatment.
In the XelQuali study, patients with unresectable 
mCRC who obtained stable disease (76%) after 4 cycles 
of first-line CapeOx treatment continued to have single-
agent capecitabine maintenance [3]. The results showed 
that the median PFS was 6.7 months, and the median OS 
was 20.5 months for all recruited patients. In the capecit-
abine maintenance subgroup, the median PFS and OS 
were 8.1 and 23.1  months, and the occurrence of AEs 
of all grades (neuropathy, diarrhea, and lethargy) was 
significantly reduced. The occurrence rates of grade 1/2 
and grade 3 AEs were 77% and 7% in the experimental 
group and were 47% and 3% in the control group. The 
results indicated that single capecitabine maintenance for 
patients obtained CR, PR, or SD after short-term CapeOx 
provided an effective and tolerable therapeutic option. 
This protocol minimized accumulated neurotoxicity by 
reducing repeated injections of oxaliplatin. It is more 
cost-effective and convenient than continuous treatment 
to be used for patients and healthcare providers [3].
The single-agent capecitabine maintenance protocol 
has been fully verified in Chinese patients with mCRC. 
Sun Yat-sen University Cancer Center conducted a phase 
II study of CapeOx as a first-line treatment followed 
by capecitabine maintenance in patients with mCRC. 
Among the 124 patients with treatment-naïve mCRC 
receiving a median 6 cycles of CapeOx, 62 with no dis-
ease progression chose discontinuation or continued 
to receive oral capecitabine (1000  mg/m2, twice daily) 
until disease progression or intolerable toxicity occurred. 
Among them, 22 received maintenance treatment. The 
patients who did or did not have maintenance treat-
ment were similar in baseline characteristics. The results 
showed that at the end of the study (median follow-up, 
20  months), 19 (86.3%) patients in the maintenance 
group were still alive (range, 8–37 months); therefore, OS 
could not be calculated. The median duration of disease 
control was superior in the maintenance group than in 
the non-maintenance group (14 vs. 9 months, P = 0.041). 
Among the 22 patients in the maintenance group, only 
1 discontinued treatment due to grade 3 hand-foot syn-
drome after receiving 2 cycles of capecitabine. Four 
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patients (18.2%) had grade 1/2 hand-foot syndrome, and 
the rest had a mild AE [16].
Sun Yat-sen University Cancer Center published the 
results of a phase III multi-center study on continuous 
capecitabine maintenance after CapeOx or FOLFOX 
in 2015 [17]. In total, 274 patients with mCRC were 
enrolled, and they were randomized at a 1:1 ratio into 
capecitabine maintenance (1000  mg/m2, twice daily for 
14 days, then chemo-free interval for 7 days; n = 136) or 
non-maintenance observation (n  =  138) after CapeOx 
or FOLFOX for 18–24  weeks. The results showed that 
the maintenance group surpassed the observation group 
in PFS (10.43 vs. 7.82  months, P  <  0.001). Two patients 
(1.5%) in the maintenance group withdrew from the 
study due to a toxic reaction, but most patients tolerated 
the treatment well.
Another similar study on capecitabine maintenance 
after first-line treatment was performed by Peking Uni-
versity Oncology Hospital, with 85 recruited mCRC 
patients obtaining controlled disease (CR, PR, or SD) 
after first-line CapeOx, FOLFOX, or FOLFIRI [4]. Thirty-
three patients chose to receive capecitabine maintenance, 
and the others were observed without maintenance. The 
results suggested a superior prognosis of the mainte-
nance group compared with the non-maintenance group. 
The median time to progression (TTP) was 9.0 months in 
the maintenance group and 6.5 months in the non-main-
tenance group (P = 0.007); OS was 40.4 and 21.9 months, 
respectively (P = 0.015). Among the patients on mainte-
nance treatment, 6 (18.2%) had grade 1 hand-foot syn-
drome, 1 (3.0%) had grade 3 diarrhea, and 1 (3.0%) had 
grade 3 thrombocytopenia. All of these events were con-
trolled by supportive treatment and did not contribute to 
early withdrawal [4].
Maintenance therapy with targeted agents
Maintenance with chemotherapy in combination 
with targeted agents
For mCRC patients responding to chemotherapy in 
combination with targeted agents, maintenance with 
less toxic chemotherapy (5-FU) and targeted agents are 
recommended. Among these schemes, the bevacizumab 
plus capecitabine regimen has the most compelling 
evidence.
In the sequential versus combination chemotherapy 
with capecitabine, irinotecan, and oxaliplatin in advanced 
colorectal cancer (CAIRO3) study, a Dutch phase III 
randomized controlled trial, mCRC patients were rand-
omized to receive bevacizumab plus capecitabine dou-
blet maintenance, or to be observed with no maintenance 
after 6 cycles of first-line CapeOx plus bevacizumab, 
and then they were re-inducted with CapeOx plus bev-
acizumab when disease progression occurred [5]. The 
results showed that the maintenance group was superior 
to the suspension group with regard to PFS, but there 
was no significant difference in QoL scores [5].
In the German AIO KRK 0207 trial, patients with 
mCRC were randomized to receive 5-FU plus bevaci-
zumab maintenance, single-agent bevacizumab main-
tenance, or no maintenance after 24  weeks of 5-FU, 
oxaliplatin plus bevacizumab triplet therapy [15]. The 
results showed that the median PFS was 6.2, 4.8, and 
3.6  months, respectively. To achieve a longer first TTP, 
5-FU plus bevacizumab is a superior maintenance 
scheme [15].
Maintenance treatment with a single targeted drug
For patients responding to chemotherapy in combination 
with targeted drugs, if they cannot tolerate a less toxic 
chemotherapy regimen, individual targeted agent main-
tenance is a possible treatment option.
In the First-Line XELOX Plus Bevacizumab Followed 
by XELOX Plus Bevacizumab or Single-Agent Bevaci-
zumab as Maintenance Therapy in Patients with Meta-
static Colorectal Cancer study, the Phase III MACRO 
TTD study, AEs were significantly reduced in patients 
with single-agent bevacizumab compared with those 
with continuous chemotherapy [18]. This study assessed 
the efficacy on patients with mCRC who switched to 
single-agent bevacizumab maintenance or continued 
the scheme after receiving CapeOx plus bevacizumab 
induction. The results showed that median PFS (9.7 vs. 
10.4  months), median OS (20.0 vs. 23.2  months), and 
response rate (49% vs. 47%) were not significantly differ-
ent between the two groups. However, the rate of AEs 
including diarrhea, food-hand reaction, and neuropathy 
was significantly higher in patients continuing chemo-
therapy than in patients switching to maintenance treat-
ment [18].
In the MACRO-2 study, patients received FOLFOX 
plus cetuximab for 8 cycles, and then they were rand-
omized to receive single-agent cetuximab maintenance 
or continuous FOLFOX plus cetuximab [19]. The results 
revealed that the efficacy of single-agent cetuximab 
maintenance was not inferior to continuous combina-
tion therapy (PFS: 8.9 vs. 9.8 months, P = 0.09; OS: 23.6 
vs. 22.2  months, P  =  0.54; response rate: 47% vs. 39%, 
P = 0.33) [19].
The combination maintenance with two or more tar-
geted agents presented an increased degree of AEs 
instead of improved benefits; therefore, epidermal 
growth factor receptor (EGFR)- and vascular endothelial 
growth factor receptor (VEGF)-targeted agent combina-
tion was not recommended.
The Panitumumab Advanced Colorectal Cancer Eval-
uation (PACCE) study found that for oxaliplatin- or 
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irinotecan-based chemotherapy in combination with 
bevacizumab, when panitumumab was added, PFS was 
significantly shortened and toxicity was significantly 
strengthened, regardless of wild-type or KRAS exon 2 
mutations [20]. Similar results were obtained from the 
CAIRO2 study by adding cetuximab to capecitabine, 
oxaliplatin, and bevacizumab [5]. Therefore, the com-
munity of experts is strongly averse to combining thera-
pies that target EGFR (cetuximab or panitumumab) and 
VEGF (bevacizumab).
Maintenance scheme for patients with first-line 
failure
There is a lack of studies on maintenance treatment for 
patients who had a first-line failure and began to receive 
second-line or higher chemotherapy alone or in combi-
nation with targeted agents. Consequently, therapeutic 
principles and options can be made in reference to rec-
ommendations for first-line treatment.
Comprehensive evaluation and prospect 
of maintenance treatment
In summary, physicians are required to manage the com-
plete process of mCRC by comprehensively considering 
the benefits for life expectancy and QoL, while also con-
sidering factors including the patient’s will, employment, 
life, and economy, to choose the most suitable treat-
ment regimen. Maintenance therapy is essential for most 
mCRC patients. As a therapeutic strategy with less tox-
icity and stable efficacy, it significantly reduced AEs and 
improved patients’ QoL. To select the scheme of main-
tenance treatment, maintenance with targeted agents 
in addition to less toxic chemotherapy (5-FU) is recom-
mended for mCRC patients responding to chemotherapy 
with a targeted treatment combination. Patients who 
underwent only chemotherapy as a first-line treatment 
can undergo less toxic chemotherapy alone. Single-agent 
capecitabine maintenance is the most evidence-based 
scheme, and it has been fully verified in Chinese patients 
with mCRC. Oral single-agent capecitabine mainte-
nance is more convenient to use; thus, it has an improved 
patient compliance.
In addition to the therapeutic strategies described 
above, investigators are exploring new therapeutic 
options. Metronomic chemotherapy is a frequent use of 
low-dose chemotherapeutics. Compared with conven-
tional large dose impact chemotherapy, metronomic 
chemotherapy is cytotoxic to tumors, and it can also 
facilitate the apoptosis of endothelial cells, suppress angi-
ogenesis, and reduce AEs. Preliminary results of in  vivo 
and in  vitro studies suggested that metronomic chemo-
therapy with capecitabine chemotherapy can suppress the 
proliferation of tumor cells in CRC, and it is comparable 
to cyclophosphamide (CTX) metronomic chemotherapy 
with respect to efficacy [21]. In a Swedish study, patients 
with KRAS mutations who achieved CR, PR, or SD by 
receiving chemotherapy in combination with bevaci-
zumab were randomized to receive a metronomic dose 
of bevacizumab or capecitabine (500 mg, oral administra-
tion, twice daily). The median PFS was 3.8 months in the 
bevacizumab group and 3.7  months in the capecitabine 
group [22]. Capecitabine metronomic chemotherapy is a 
novel scheme that merits testing. Its efficacy and safety in 
mCRC patient maintenance requires further study.
Many questions about maintenance therapy remain 
unanswered, e.g., what kind of patients can achieve the 
best benefits from maintenance therapy? Is there any rel-
evant biomarker to identify them? In existing studies, fol-
low-up treatment schedule following disease progression 
is also a focus of future exploration. Answers to these 
questions will aid the identification of the best therapeu-
tic strategy for patients with late-stage CRC.
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